Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which
included a dose titration period. An additional transition period occurred for those patients
who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients
with PAH were enrolled.